Literature DB >> 3990720

Anaphylactic reaction to intravenous cyclosporine.

B Chapuis, C Helg, M Jeannet, G Zulian, P Huber, P Gumovski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3990720     DOI： 10.1056/NEJM198505093121915

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

Review 2.  Complications of cyclosporin therapy.

Authors:  B D Kahan; S M Flechner; M I Lorber; C Jensen; D Golden; C T Van Buren
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

Review 3.  Adverse drug events related to dosage forms and delivery systems.

Authors:  I F Uchegbu; A T Florence
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

4.  Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia.

Authors:  H L McLeod; D K Baker; C H Pui; J H Rodman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Novel taxol formulations: preparation and characterization of taxol-containing liposomes.

Authors:  A Sharma; R M Straubinger
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

Review 6.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

7.  Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.

Authors:  F Doz; J C Gentet; F Pein; D Frappaz; P Chastagner; S Moretti; G Vassal; J Arditti; O V Tellingen; A Iliadis; J Catalin
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

8.  Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL.

Authors:  Karl Henrik Johannes Ehinger; Magnus Joakim Hansson; Fredrik Sjövall; Eskil Elmér
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.